IS6425A - Nýir sertralínhýdróklóríð fjölgervingar, aðferðirtil að búa þá til, blöndur sem innihalda þá og aðferðir til að nota þá - Google Patents

Nýir sertralínhýdróklóríð fjölgervingar, aðferðirtil að búa þá til, blöndur sem innihalda þá og aðferðir til að nota þá

Info

Publication number
IS6425A
IS6425A IS6425A IS6425A IS6425A IS 6425 A IS6425 A IS 6425A IS 6425 A IS6425 A IS 6425A IS 6425 A IS6425 A IS 6425A IS 6425 A IS6425 A IS 6425A
Authority
IS
Iceland
Prior art keywords
methods
sertraline hydrochloride
polyphenols
making
new
Prior art date
Application number
IS6425A
Other languages
English (en)
Inventor
Aronhime Judith
Mendelovici Marioana
Nidam Tamar
Singer Claude
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of IS6425A publication Critical patent/IS6425A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS6425A 1999-12-21 2002-06-18 Nýir sertralínhýdróklóríð fjölgervingar, aðferðirtil að búa þá til, blöndur sem innihalda þá og aðferðir til að nota þá IS6425A (is)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17134199P 1999-12-21 1999-12-21
US18733600P 2000-03-06 2000-03-06
US18791000P 2000-03-08 2000-03-08
US19060300P 2000-03-20 2000-03-20
PCT/US2000/035178 WO2001045692A1 (en) 1999-12-21 2000-12-21 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Publications (1)

Publication Number Publication Date
IS6425A true IS6425A (is) 2002-06-18

Family

ID=27496950

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6425A IS6425A (is) 1999-12-21 2002-06-18 Nýir sertralínhýdróklóríð fjölgervingar, aðferðirtil að búa þá til, blöndur sem innihalda þá og aðferðir til að nota þá

Country Status (19)

Country Link
US (2) US6452054B2 (is)
EP (2) EP1797875A3 (is)
JP (2) JP4057295B2 (is)
KR (1) KR100791872B1 (is)
CN (1) CN1434708A (is)
AT (1) ATE354358T1 (is)
AU (1) AU780771B2 (is)
DE (1) DE60033566T2 (is)
DK (1) DK1248605T3 (is)
ES (1) ES2281374T3 (is)
HR (1) HRP20020543A2 (is)
HU (1) HUP0204010A3 (is)
IL (1) IL150332A0 (is)
IS (1) IS6425A (is)
PL (1) PL356452A1 (is)
PT (1) PT1248605E (is)
SK (1) SK8872002A3 (is)
WO (1) WO2001045692A1 (is)
YU (1) YU47902A (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5845313A (en) 1995-07-31 1998-12-01 Lexar Direct logical block addressing flash memory mass storage architecture
US6978342B1 (en) 1995-07-31 2005-12-20 Lexar Media, Inc. Moving sectors within a block of information in a flash memory mass storage architecture
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) * 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
TWI260315B (en) 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
JP4057295B2 (ja) 1999-12-21 2008-03-05 テバ ファーマシューティカル インダストリーズ リミティド 新規塩酸セルトラリン多形体、それらを調製するための方法、それらを含有する組成物およびそれらを用いる方法
IL151691A0 (en) * 2000-03-14 2003-04-10 Teva Pharma Novel process for preparing (+)-cis-sertraline
EP1397343A1 (en) 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
CA2448300A1 (en) * 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline intermediates
GB0123421D0 (en) 2001-09-28 2001-11-21 Memquest Ltd Power management system
CA2483569A1 (en) * 2002-04-29 2003-11-13 Tamar Nidam Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
JP2007502329A (ja) 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
EP1660432A2 (en) * 2003-09-05 2006-05-31 Teva Pharmaceutical Industries Limited A recycling process for preparing sertraline
CA2544684A1 (en) * 2003-11-04 2005-05-26 Cipla Limited Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
US7464306B1 (en) 2004-08-27 2008-12-09 Lexar Media, Inc. Status of overall health of nonvolatile memory
US7345201B2 (en) * 2005-02-23 2008-03-18 Teva Pharmaceutical Industries, Ltd. Processes for preparing sertraline
WO2006103506A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Sertraline-containing pharmaceutical compositions and a process for preparation thereof
GB0507090D0 (en) * 2005-04-07 2005-05-11 Sandoz Ag Process for preparing polymorphic form ll of sertraline hydrochloride
US7518019B2 (en) * 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
FR2928148B1 (fr) * 2008-02-28 2013-01-18 Sanofi Aventis Procede de preparation de combretastatine
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
ES2217748T3 (es) 1998-03-18 2004-11-01 Ciba Specialty Chemicals Holding Inc. Procedimiento para la hidrogenacin catalitica cis-selectiva de ciclohexilidenaminas.
JP2000026379A (ja) * 1998-07-08 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンメタノール和物および塩酸セルトラリンエタノール和物、ならびにそれらの製法
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
ES2255320T3 (es) * 1998-11-27 2006-06-16 Teva Pharmaceutical Industries Ltd. Forma v clorhidrato de sertralina.
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
TWI260315B (en) * 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
JP4057295B2 (ja) * 1999-12-21 2008-03-05 テバ ファーマシューティカル インダストリーズ リミティド 新規塩酸セルトラリン多形体、それらを調製するための方法、それらを含有する組成物およびそれらを用いる方法
IN192343B (is) 2000-05-26 2004-04-10 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
WO2001045692A9 (en) 2002-07-04
DE60033566T2 (de) 2007-10-25
US6858652B2 (en) 2005-02-22
EP1248605B1 (en) 2007-02-21
JP2003518056A (ja) 2003-06-03
DE60033566D1 (de) 2007-04-05
EP1248605A2 (en) 2002-10-16
US6452054B2 (en) 2002-09-17
JP4057295B2 (ja) 2008-03-05
US20010041815A1 (en) 2001-11-15
HUP0204010A2 (hu) 2003-04-28
HRP20020543A2 (en) 2005-04-30
ATE354358T1 (de) 2007-03-15
YU47902A (sh) 2005-11-28
AU2737601A (en) 2001-07-03
PT1248605E (pt) 2007-03-30
CN1434708A (zh) 2003-08-06
US20030023117A1 (en) 2003-01-30
WO2001045692A1 (en) 2001-06-28
EP1797875A2 (en) 2007-06-20
EP1248605A4 (en) 2004-11-24
DK1248605T3 (da) 2007-03-19
EP1797875A3 (en) 2007-08-29
SK8872002A3 (en) 2002-12-03
ES2281374T3 (es) 2007-10-01
JP2007308505A (ja) 2007-11-29
IL150332A0 (en) 2002-12-01
PL356452A1 (en) 2004-06-28
KR20020062356A (ko) 2002-07-25
KR100791872B1 (ko) 2008-01-07
AU780771B2 (en) 2005-04-14
HUP0204010A3 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
IS6425A (is) Nýir sertralínhýdróklóríð fjölgervingar, aðferðirtil að búa þá til, blöndur sem innihalda þá og aðferðir til að nota þá
ES2164842T3 (es) Procedimiento para la preparacion de composiciones de microcapsulas.
IS6003A (is) Mónóamín endurupptökulatar til meðhöndlunar á truflunum í miðtaugakerfi
UY26130A1 (es) Compuestos para tratar la obesidad
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
BR0113234A (pt) Polimorfos de um análogo de epotilona
BR0113286A (pt) Pirazóis substituìdos
SV1998000153A (es) Proceso para la sintesis de 1,3-dioles
ATE334662T1 (de) Herstellungsverfahren von arzneizubereitungen
ECSP055584A (es) Proceso para la preparación de fibrinógeno
BRPI0518841A2 (pt) derivados de indenila e uso destes para o tratamento de transtornos neurolàgicos
MXPA02011288A (es) Tioacetamidas substituidas.
ATE329588T1 (de) Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen
PT1414816E (pt) Polimorfo estavel da flibanserina, processo tecnico para a sua preparacao e sua utilizacao na preparacao de medicamentos
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60139466D1 (de) Behandlung von diabetes
HUP0204318A2 (en) Torsemide polymorphic forms, process for their preparation, pharmaceutical compositions containing them and their use
BR0200249A (pt) Misturas de borracha contendo terpolìmeros
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
NO20023150L (no) Fremgangsmate for fremstilling av citalopram
DK0417003T3 (da) Anvendelse af antiprogestomimetiske forbindelser til fremme af ovulation
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
YU42098A (sh) Upotreba olanzapina